BerandaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$3,75
Rentang hari
$3,72 - $3,74
Rentang tahun
$3,36 - $7,60
Kapitalisasi pasar
144,10 jt USD
Volume Rata-Rata
3,66 rb
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CHF) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 3,99 jt | -10,05% |
Laba bersih | -20,40 jt | -35,25% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,56 | — |
EBITDA | -14,15 jt | 7,98% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 114,49 jt | -28,05% |
Total aset | 124,25 jt | -27,17% |
Total liabilitas | 17,59 jt | 16,89% |
Total ekuitas | 106,66 jt | — |
Saham yang beredar | 37,39 jt | — |
Harga terhadap nilai buku | 1,32 | — |
Tingkat pengembalian aset | -27,70% | — |
Tingkat pengembalian modal | -30,77% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -20,40 jt | -35,25% |
Kas dari operasi | -13,10 jt | 16,68% |
Kas dari investasi | 14,97 jt | 13,85% |
Kas dari pembiayaan | -243,00 rb | 8,99% |
Perubahan kas bersih | 603,00 rb | 122,68% |
Arus kas bebas | -3,61 jt | 63,16% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
153
